{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:51:21Z","timestamp":1795107081739,"version":"4.10.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01268-y","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T18:30:06Z","timestamp":1744050606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Real-World International Staging System (RW-ISS) for patients with newly diagnosed multiple myeloma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4863","authenticated-orcid":false,"given":"Tobias Schmidt","family":"Sl\u00f8rdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten N\u00f8rgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9943-7007","authenticated-orcid":false,"given":"Agoston Gyula","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"1268_CR1","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"1268_CR2","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","volume":"117","author":"H Avet-Loiseau","year":"2011","unstructured":"Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117:2009\u201311.","journal-title":"Blood"},{"key":"1268_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00933-4","volume":"13","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Perrot A, Cazaubiel T, Leleu X, Montes L, Jacquet C, et al. Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions. Blood Cancer J. 2023;13:160.","journal-title":"Blood Cancer J"},{"key":"1268_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0307-4","volume":"10","author":"R Mina","year":"2020","unstructured":"Mina R, Joseph NS, Gay F, Kastritis E, Petrucci MT, Kaufman JL, et al. Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood Cancer J. 2020;10:40.","journal-title":"Blood Cancer J"},{"key":"1268_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.25758","volume":"95","author":"S Goldman-Mazur","year":"2020","unstructured":"Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grz\u0105\u015bko N, Radocha J, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020;95:503\u20139.","journal-title":"Am J Hematol"},{"key":"1268_CR6","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1002\/cam4.1620","volume":"7","author":"J Radocha","year":"2018","unstructured":"Radocha J, Maisnar V, Pour L, \u0160pi\u010dka I, Mina\u0159\u00edk J, Szeligov\u00e1 L, et al. Validation of multiple myeloma risk stratification indices in routine clinical practice: analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Cancer Med. 2018;7:4132\u201345.","journal-title":"Cancer Med"},{"key":"1268_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3324\/haematol.2016.145078","volume":"102","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, et al. Evaluation of the revised international staging system in an independent cohort of unselected patients with multiple myeloma. Haematologica. 2017;102:593\u20139.","journal-title":"Haematologica"},{"key":"1268_CR8","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) Report Within the HARMONY Project. J Clin Oncol. 2022;40:3406\u201318.","journal-title":"J Clin Oncol"},{"key":"1268_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ejh.13707","volume":"108","author":"CH Blimark","year":"2022","unstructured":"Blimark CH, Vangsted AJ, Klausen TW, Gregersen H, Szabo AG, Hermansen E, et al. Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. Eur J Haematol. 2022;108:99\u2013108.","journal-title":"Eur J Haematol"},{"key":"1268_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41375-018-0272-0","volume":"33","author":"TW Klausen","year":"2019","unstructured":"Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Frolund UC, Gimsing P, et al. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia. 2019;33:546\u20139.","journal-title":"Leukemia"},{"key":"1268_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00474-8","volume":"11","author":"TM Schmidt","year":"2021","unstructured":"Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021;11:83.","journal-title":"Blood Cancer J"},{"key":"1268_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CLEP.S99463","volume":"8","author":"P Gimsing","year":"2016","unstructured":"Gimsing P, Holmstrom MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;8:583\u20137.","journal-title":"Clin Epidemiol"},{"key":"1268_CR13","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1268_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/CLEP.S314959","volume":"13","author":"K Laugesen","year":"2021","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533\u201354.","journal-title":"Clin Epidemiol"},{"key":"1268_CR15","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1097\/HS9.0000000000000831","volume":"7","author":"A Panopoulou","year":"2023","unstructured":"Panopoulou A, Easdale S, Ethell M, Nicholson E, Potter M, Giotas A, et al. Impact of ultra high-risk genetics on real-world outcomes of transplant-eligible multiple myeloma patients. Hemasphere. 2023;7:e831.","journal-title":"Hemasphere"},{"key":"1268_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01149-w","volume":"14","author":"PG Richardson","year":"2024","unstructured":"Richardson PG, Perrot A, Mikhael J, Martin T, Beksac M, Spicka I, et al. Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer J. 2024;14:209.","journal-title":"Blood Cancer J"},{"key":"1268_CR17","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"J Bahlo","year":"2016","unstructured":"Bahlo J, Kutsch N, Bauer K, Bergmann MA, Byrd J, Chaffee KG, et al. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390.","journal-title":"Lancet Oncol"},{"key":"1268_CR18","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555\u201362.","journal-title":"J Clin Oncol"},{"key":"1268_CR19","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"1268_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558\u201365.","journal-title":"Blood"},{"key":"1268_CR21","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","volume":"33","author":"E Kastritis","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, et al. A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia. 2019;33:2654\u201361.","journal-title":"Leukemia"},{"key":"1268_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N. Engl J Med. 1998;339:1506\u201314.","journal-title":"N. Engl J Med"},{"key":"1268_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","volume":"34","author":"C Pawlyn","year":"2020","unstructured":"Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34:604\u201312.","journal-title":"Leukemia"},{"key":"1268_CR24","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","volume":"34","author":"G Cook","year":"2020","unstructured":"Cook G, Larocca A, Facon T, Zweegman S, Engelhardt M. Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network. Leukemia. 2020;34:2285\u201394.","journal-title":"Leukemia"},{"key":"1268_CR25","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/s41375-018-0142-9","volume":"32","author":"A Larocca","year":"2018","unstructured":"Larocca A, Dold SM, Zweegman S, Terpos E, W\u00e4sch R, D\u2019Agostino M, et al. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018;32:1697\u2013712.","journal-title":"Leukemia"},{"key":"1268_CR26","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","volume":"91","author":"P Milani","year":"2016","unstructured":"Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91:1129\u201334.","journal-title":"Am J Hematol"},{"key":"1268_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.14283\/jfa.2019.25","volume":"8","author":"H Mian","year":"2019","unstructured":"Mian H, Brouwers M, Kouroukis CT, Wildes TM. Comparison of frailty scores in newly diagnosed patients with multiple myeloma: a review. J Frailty Aging. 2019;8:215\u201321.","journal-title":"J Frailty Aging"},{"key":"1268_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z, Roost Clausen M, Ludvigsen Al-Mashhadi A, Pedersen RS, et al. Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J. 2023;13:157.","journal-title":"Blood Cancer J"},{"key":"1268_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41746-024-01132-6","volume":"7","author":"R Agius","year":"2024","unstructured":"Agius R, Riis-Jensen AC, Wimmer B, da Cunha-Bang C, Murray DD, Poulsen CB, et al. Deployment and validation of the CLL treatment infection model adjoined to an EHR system. NPJ Digit Med. 2024;7:147.","journal-title":"NPJ Digit Med"},{"key":"1268_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/CLEP.S479672","volume":"17","author":"C Brieghel","year":"2025","unstructured":"Brieghel C, Werling M, Frederiksen CM, Parviz M, Lacoppidan T, Faitova T, et al. The Danish Lymphoid Cancer Research (DALY-CARE) Data Resource: the basis for developing data-driven hematology. Clin Epidemiol. 2025;17:131\u201345.","journal-title":"Clin Epidemiol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01268-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01268-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01268-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:40:57Z","timestamp":1744216857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01268-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01268-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CB received travel grants from AbbVie outside this study. TSS has received honoraria from Takeda, Celgene, Amgen, Janssen, AbbVie, Pfizer; Consultancy for Bristol Myers Squibb, GSK, Pfizer, Menarini Group, and advisory board consultancy from Sanofi, Bristol Myers Squibb, Sanofi, Amgen, Celgene, GSK, and Janssen outside this study. CUN received research funding and\/or consultancy fees from AstraZeneca, Janssen, AbbVie, Beigene, Genmab, CSL Behring, Octapharma, Takeda, Eli Lily, MSD, and Novo Nordisk Foundation. ST has received honoraria for scientific talks from AbbVie and Thermo Fisher Scientific. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}